Istvan Laszlovszky
Overview
Explore the profile of Istvan Laszlovszky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Czobor P, Sebe B, Acsai K, Barabassy A, Laszlovszky I, Nemeth G, et al.
Front Psychiatry
. 2022 May;
13:816339.
PMID: 35546918
Introduction: Minimum clinically important difference (MCID) is a measure that defines the minimum amount of change in an objective score of a clinical test that must be reached for that...
2.
Kiss B, Kramos B, Laszlovszky I
Front Psychiatry
. 2022 Apr;
13:785592.
PMID: 35401257
Dysfunctions of the dopaminergic system are believed to play a major role in the core symptoms of schizophrenia such as positive, negative, and cognitive symptoms. The first line of treatment...
3.
McIntyre R, Daniel D, Vieta E, Laszlovszky I, Goetghebeur P, Earley W, et al.
CNS Spectr
. 2022 Feb;
28(3):319-330.
PMID: 35193729
Objective: To investigate the effect of cariprazine on cognitive symptom change across bipolar I disorder and schizophrenia. Methods: Post hoc analyses of 3- to 8-week pivotal studies in bipolar I...
4.
Barbara S, Barabassy A, Buksa K, Laszlovszky I, Dombi Z, Nemeth G, et al.
Psychiatr Hung
. 2021 Dec;
36(4):546-556.
PMID: 34939572
Introduction: People with schizophrenia often need long-term support in their everyday life. Thus, caregivers are vital factors to support their recovery and long-term functioning. In turn, however, the caregiver role...
5.
Demyttenaere K, Leenaerts N, Acsai K, Sebe B, Laszlovszky I, Barabassy A, et al.
Eur Psychiatry
. 2021 Oct;
65(1):e18.
PMID: 34641986
Background: The Positive and Negative Syndrome Scale (PANSS) is widely used in schizophrenia and has been divided into distinct factors (5-factor models) and subfactors. Network analyses are newer in psychiatry...
6.
Nemeth G, Dombi Z, Laszlovszky I, Barabassy A
Expert Opin Pharmacother
. 2021 Aug;
23(12):1467-1468.
PMID: 34431422
No abstract available.
7.
Laszlovszky I, Barabassy A, Nemeth G
Adv Ther
. 2021 Jun;
38(7):3652-3673.
PMID: 34091867
Schizophrenia is characterized by positive, negative, cognitive, and affective symptoms. Antipsychotic medications, which work by blocking the dopamine D receptor, are the foundation of pharmacotherapy for schizophrenia to control positive...
8.
Barabassy A, Sebe B, Acsai K, Laszlovszky I, Szatmari B, Earley W, et al.
Neuropsychiatr Dis Treat
. 2021 Apr;
17:957-970.
PMID: 33854317
Background: Long-term treatment with antipsychotic agents is indicated for patients with schizophrenia, but treatment is associated with adverse events (AEs) that contribute to medication discontinuation and nonadherence. Understanding drug safety...
9.
Kiss B, Laszlovszky I, Kramos B, Visegrady A, Bobok A, Levay G, et al.
Biomolecules
. 2021 Jan;
11(1).
PMID: 33466844
Dopamine (DA), as one of the major neurotransmitters in the central nervous system (CNS) and periphery, exerts its actions through five types of receptors which belong to two major subfamilies...
10.
Szatmari B, Barabassy A, Harsanyi J, Laszlovszky I, Sebe B, Gal M, et al.
Front Psychiatry
. 2020 Mar;
11:61.
PMID: 32194443
Schizophrenia is a life-long mental disorder, affecting young adolescents to elderly patients. Antipsychotic treatment is indicated for all patients with schizophrenia, including the very young and old as well. Developmental...